Details of the Drug

General Information of Drug (ID: DM2AQ5N)

Drug Name

Spironolactone

Synonyms

Abbolactone; Acelat; Aldace; Aldactazide; Aldactide; Aldactone; Alderon; Aldopur; Almatol; Altex; Aquareduct; Deverol; Diatensec; Dira; Duraspiron; Espironolactona; Euteberol; Flumach; Frumikal; Jenaspiron; Lacalmin; Lacdene; Laractone; Melarcon; Nefurofan; NovoSpiroton; Osyrol; Practon; SNL; Sagisal; Sincomen; Spiractin; Spiresis; Spiretic; Spiridon; Spirobeta; Spiroctan; Spiroctanie; Spiroderm; Spirogamma; Spirolactone; Spirolakton; Spirolang; Spirolone; Spirone; Spironocompren; Spironolactonum; Spironolattone; Spironone; Spirospare; Sprioderm; Suracton; Uractone; Urusonin; Veroshpiron; Verospiron; Verospirone; Xenalon; Aldactone A; Alphapharm Brand of Spironolactone; Alpharma Brand of Spironolactone; Alter Brand of Spironolactone; Ashbourne Brand of Spironolactone; Azupharma Brand of Spironolactone; Betapharm Brand of Spironolactone; Cardel Brand of Spironolactone; Ct Arzneimittel Brand of Spironolactone; Dexo Brand of Spironolactone; Espironolactona Alter; Espironolactona Mundogen; Generosan Brand of Spironolactone; Hormosan Brand of Spironolactone; Jenapharm Brand of Spironolactone; Merck dura Brand of Spironolactone; Mundogen Brand of Spironolactone; Novo Spiroton; Novopharm Brand of Spironolactone; Pfizer Brand of Spironolactone; Pharmafrid Brand of Spironolactone; Roche Brand of Spironolactone; Searle Brand of Spironolactone; Spiro von ct; Spirono Isis; Spironolactone A; Spironolattone [DCIT]; Verospirone Opianin; Worwag Brand of Spironolactone; LT00772287; SC 9420; SC9420; Aldactazide (TN); Aldactone (TN); Berlactone (TN); Ct-Arzneimittel Brand of Spironolactone; Espironolactona [INN-Spanish]; Mayoly-Spindler Brand of Spironolactone; Novo-Spiroton; SC-9420; Spiractin (TN); Spiro-Tablinen; Spirono-Isis; Spironolactonum [INN-Latin]; Spirotone (TN); Supra-puren; Verospiron (TN); Von ct, spiro; Novo-Spiroton (TN); Spironolactone [BAN:INN:JAN]; Spironolactone [INN:BAN:JAN]; Spiro L.U.T.; Spironolactone (JP15/USP/INN); Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]; Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan); 4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate; 7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone; 7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone

Indication

Disease Entry	ICD 11	Status	REF
Chronic heart failure	BD1Z	Approved	[1]
Congestive heart failure	BD10	Approved	[2]
Edema	MG29	Approved	[1]
Hyperaldosteronism	5A72	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[3]
------------------------------------------------------------------------------------

Therapeutic Class

Diuretics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

416.6

Logarithm of the Partition Coefficient (xlogp)

2.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Elimination: 0.5% of drug is excreted from urine in the unchanged form [4]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 13.71714 micromolar/kg/day [5]
Water Solubility: The ability of drug to dissolve in water is measured as 0.022 mg/mL [4]

Chemical Identifiers

Formula: C24H32O4S
IUPAC Name: S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate
Canonical SMILES: CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C
InChI: InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1
InChIKey: LXMSZDCAJNLERA-ZHYRCANASA-N

Cross-matching ID

PubChem CID: 5833
ChEBI ID: CHEBI:9241
CAS Number: 52-01-7
DrugBank ID: DB00421
TTD ID: D0EP0C
VARIDT ID: DR00609
ACDINA ID: D00638

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Mineralocorticoid receptor (MR)	TT26PHO	MCR_HUMAN	Modulator	[6]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Protein Interaction/Cellular Processes	[7]
Angiotensinogen (AGT)	OTBZLYR3	ANGT_HUMAN	Gene/Protein Processing	[8]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[9]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[10]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[11]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Gene/Protein Processing	[11]
Collagen alpha-1(III) chain (COL3A1)	OTT1EMLM	CO3A1_HUMAN	Gene/Protein Processing	[12]
Cytochrome P450 2C8 (CYP2C8)	OTHCWT42	CP2C8_HUMAN	Gene/Protein Processing	[13]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Gene/Protein Processing	[14]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Gene/Protein Processing	[15]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Chronic heart failure

ICD Disease Classification

BD1Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Mineralocorticoid receptor (MR)	DTT	NR3C2	7.31E-01	-5.31E-04	-1.53E-03

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Spironolactone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Eplerenone	DMF0NQR	Major	Increased risk of hyperkalemia by the combination of Spironolactone and Eplerenone.	Heart failure [BD10-BD1Z]	[16]
Carvedilol	DMHTEAO	Moderate	Increased risk of hyperglycemia by the combination of Spironolactone and Carvedilol.	Heart failure [BD10-BD1Z]	[17]
Amiloride	DMRTSGP	Major	Increased risk of hyperkalemia by the combination of Spironolactone and Amiloride.	Heart failure [BD10-BD1Z]	[18]
-----------

Coadministration of a Drug Treating the Disease Different from Spironolactone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Idarubicin	DMM0XGL	Moderate	Decreased clearance of Spironolactone due to the transporter inhibition by Idarubicin.	Acute myeloid leukaemia [2A60]	[19]
Daunorubicin	DMQUSBT	Moderate	Decreased clearance of Spironolactone due to the transporter inhibition by Daunorubicin.	Acute myeloid leukaemia [2A60]	[19]
Gilteritinib	DMTI0ZO	Moderate	Decreased metabolism of Spironolactone caused by Gilteritinib mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[20]
Linezolid	DMGFPU2	Moderate	Additive hypotensive effects by the combination of Spironolactone and Linezolid.	Bacterial infection [1A00-1C4Z]	[21]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Spironolactone and Cariprazine.	Bipolar disorder [6A60]	[22]
Loperamide	DMOJZQ9	Major	Decreased clearance of Spironolactone due to the transporter inhibition by Loperamide.	Bowel habit change [ME05]	[23]
Talazoparib	DM1KS78	Moderate	Decreased clearance of Spironolactone due to the transporter inhibition by Talazoparib.	Breast cancer [2C60-2C6Y]	[24]
Bosutinib	DMTI8YE	Moderate	Decreased metabolism of Spironolactone caused by Bosutinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[20]
Sotalol	DML60TN	Moderate	Increased risk of hypertriglyceridemia by the combination of Spironolactone and Sotalol.	Cardiac arrhythmia [BC9Z]	[17]
Pentosan polysulfate	DM2HRKE	Moderate	Increased risk of hyperkalemia by the combination of Spironolactone and Pentosan polysulfate.	Chronic pain [MG30]	[25]
Phenylbutazone	DMAYL0T	Moderate	Antagonize the effect of Spironolactone when combined with Phenylbutazone.	Chronic pain [MG30]	[26]
Ketoprofen	DMRKXPT	Moderate	Antagonize the effect of Spironolactone when combined with Ketoprofen.	Chronic pain [MG30]	[26]
Levomilnacipran	DMV26S8	Moderate	Increased risk of hyponatremia by the combination of Spironolactone and Levomilnacipran.	Chronic pain [MG30]	[27]
Fidaxomicin	DMFP6MV	Minor	Decreased clearance of Spironolactone due to the transporter inhibition by Fidaxomicin.	Clostridium difficile enterocolitis [1A04]	[28]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Spironolactone and Olopatadine.	Conjunctiva disorder [9A60]	[29]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Spironolactone and Drospirenone.	Contraceptive management [QA21]	[30]
Ardeparin	DMYRX8B	Moderate	Increased risk of hyperkalemia by the combination of Spironolactone and Ardeparin.	Coronary thrombosis [BA43]	[20]
Sertraline	DM0FB1J	Moderate	Increased risk of hyponatremia by the combination of Spironolactone and Sertraline.	Depression [6A70-6A7Z]	[27]
Fluoxetine	DM3PD2C	Moderate	Increased risk of hyponatremia by the combination of Spironolactone and Fluoxetine.	Depression [6A70-6A7Z]	[27]
Vilazodone	DM4LECQ	Moderate	Increased risk of hyponatremia by the combination of Spironolactone and Vilazodone.	Depression [6A70-6A7Z]	[27]
Paroxetine	DM5PVQE	Moderate	Increased risk of hyponatremia by the combination of Spironolactone and Paroxetine.	Depression [6A70-6A7Z]	[27]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Spironolactone and Selegiline.	Depression [6A70-6A7Z]	[21]
Vortioxetine	DM6F1PU	Moderate	Increased risk of hyponatremia by the combination of Spironolactone and Vortioxetine.	Depression [6A70-6A7Z]	[27]
Duloxetine	DM9BI7M	Moderate	Increased risk of hyponatremia by the combination of Spironolactone and Duloxetine.	Depression [6A70-6A7Z]	[27]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Spironolactone and Isocarboxazid.	Depression [6A70-6A7Z]	[21]
Milnacipran	DMBFE74	Moderate	Increased risk of hyponatremia by the combination of Spironolactone and Milnacipran.	Depression [6A70-6A7Z]	[27]
Escitalopram	DMFK9HG	Moderate	Increased risk of hyponatremia by the combination of Spironolactone and Escitalopram.	Depression [6A70-6A7Z]	[27]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Spironolactone and Tranylcypromine.	Depression [6A70-6A7Z]	[21]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of hyponatremia by the combination of Spironolactone and Desvenlafaxine.	Depression [6A70-6A7Z]	[27]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Spironolactone and OPC-34712.	Depression [6A70-6A7Z]	[22]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Spironolactone and Phenelzine.	Depression [6A70-6A7Z]	[21]
Carbamazepine	DMZOLBI	Moderate	Increased risk of hyponatremia by the combination of Spironolactone and Carbamazepine.	Epilepsy/seizure [8A61-8A6Z]	[31]
Eslicarbazepine	DMZREFQ	Moderate	Increased risk of hyponatremia by the combination of Spironolactone and Eslicarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[32]
Nadolol	DMW6GVL	Moderate	Increased risk of ventricular arrhythmias by the combination of Spironolactone and Nadolol.	Essential hypertension [BA00]	[17]
Mefenamic acid	DMK7HFI	Moderate	Antagonize the effect of Spironolactone when combined with Mefenamic acid.	Female pelvic pain [GA34]	[26]
Ripretinib	DM958QB	Moderate	Decreased clearance of Spironolactone due to the transporter inhibition by Ripretinib.	Gastrointestinal stromal tumour [2B5B]	[33]
Carteolol	DMFMDOB	Moderate	Increased risk of ventricular arrhythmias by the combination of Spironolactone and Carteolol.	Glaucoma [9C61]	[17]
Metipranolol	DMJMVKI	Moderate	Increased risk of ventricular arrhythmias by the combination of Spironolactone and Metipranolol.	Glaucoma [9C61]	[17]
Levobunolol	DMTNFCQ	Moderate	Increased risk of hyperglycemia by the combination of Spironolactone and Levobunolol.	Glaucoma [9C61]	[17]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Spironolactone and Procarbazine.	Hodgkin lymphoma [2B30]	[21]
Brentuximab vedotin	DMWLC57	Moderate	Decreased clearance of Spironolactone due to the transporter inhibition by Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[34]
Fostemsavir	DM50ILT	Moderate	Decreased metabolism of Spironolactone caused by Fostemsavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Eprosartan	DM07K2I	Major	Increased risk of hyperkalemia by the combination of Spironolactone and Eprosartan.	Hypertension [BA00-BA04]	[36]
Acebutolol	DM0TI4U	Moderate	Increased risk of hypertriglyceridemia by the combination of Spironolactone and Acebutolol.	Hypertension [BA00-BA04]	[17]
Aliskiren	DM1BV7W	Moderate	Increased risk of hyperkalemia by the combination of Spironolactone and Aliskiren.	Hypertension [BA00-BA04]	[37]
Moexipril	DM26E4B	Major	Increased risk of hyperkalemia by the combination of Spironolactone and Moexipril.	Hypertension [BA00-BA04]	[38]
Bisoprolol	DM3UZ95	Moderate	Increased risk of hypertriglyceridemia by the combination of Spironolactone and Bisoprolol.	Hypertension [BA00-BA04]	[17]
Captopril	DM458UM	Major	Increased risk of hyperkalemia by the combination of Spironolactone and Captopril.	Hypertension [BA00-BA04]	[38]
Trandolapril	DM4L6EU	Major	Increased risk of hyperkalemia by the combination of Spironolactone and Trandolapril.	Hypertension [BA00-BA04]	[38]
Losartan	DM72JXH	Major	Increased risk of hyperkalemia by the combination of Spironolactone and Losartan.	Hypertension [BA00-BA04]	[36]
Nebivolol	DM7F1PA	Moderate	Increased risk of hyperglycemia by the combination of Spironolactone and Nebivolol.	Hypertension [BA00-BA04]	[17]
Fosinopril	DM9NJ52	Major	Increased risk of hyperkalemia by the combination of Spironolactone and Fosinopril.	Hypertension [BA00-BA04]	[38]
TAK-491	DMCF6SX	Major	Increased risk of hyperkalemia by the combination of Spironolactone and TAK-491.	Hypertension [BA00-BA04]	[36]
Pindolol	DMD2NV7	Moderate	Increased risk of hyperglycemia by the combination of Spironolactone and Pindolol.	Hypertension [BA00-BA04]	[17]
Benazepril	DMH1M9B	Major	Increased risk of hyperkalemia by the combination of Spironolactone and Benazepril.	Hypertension [BA00-BA04]	[38]
Labetalol	DMK8U72	Moderate	Increased risk of hyperglycemia by the combination of Spironolactone and Labetalol.	Hypertension [BA00-BA04]	[17]
Enalapril	DMNFUZR	Major	Increased risk of hyperkalemia by the combination of Spironolactone and Enalapril.	Hypertension [BA00-BA04]	[38]
Perindopril	DMOPZDT	Major	Increased risk of hyperkalemia by the combination of Spironolactone and Perindopril.	Hypertension [BA00-BA04]	[38]
Quinapril	DMR8H31	Major	Increased risk of hyperkalemia by the combination of Spironolactone and Quinapril.	Hypertension [BA00-BA04]	[38]
Telmisartan	DMS3GX2	Major	Increased risk of hyperkalemia by the combination of Spironolactone and Telmisartan.	Hypertension [BA00-BA04]	[36]
Irbesartan	DMTP1DC	Major	Increased risk of hyperkalemia by the combination of Spironolactone and Irbesartan.	Hypertension [BA00-BA04]	[36]
Lisinopril	DMUOK4C	Major	Increased risk of hyperkalemia by the combination of Spironolactone and Lisinopril.	Hypertension [BA00-BA04]	[38]
Potassium chloride	DMMTAJC	Major	Increased risk of hyperkalemia by the combination of Spironolactone and Potassium chloride.	Hypo-kalaemia [5C77]	[39]
Tolvaptan	DMIWFRL	Moderate	Decreased clearance of Spironolactone due to the transporter inhibition by Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[40]
Meclofenamic acid	DM05FXR	Moderate	Antagonize the effect of Spironolactone when combined with Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[26]
Berotralstat	DMWA2DZ	Major	Decreased clearance of Spironolactone due to the transporter inhibition by Berotralstat.	Innate/adaptive immunodeficiency [4A00]	[41]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Spironolactone and Propiomazine.	Insomnia [7A00-7A0Z]	[22]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Spironolactone and ITI-007.	Insomnia [7A00-7A0Z]	[22]
GDC-0199	DMH0QKA	Major	Decreased clearance of Spironolactone due to the transporter inhibition by GDC-0199.	Mature B-cell leukaemia [2A82]	[33]
Ubrogepant	DM749I3	Moderate	Decreased clearance of Spironolactone due to the transporter inhibition by Ubrogepant.	Migraine [8A80]	[42]
Propranolol	DM79NTF	Moderate	Increased risk of ventricular arrhythmias by the combination of Spironolactone and Propranolol.	Migraine [8A80]	[17]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Spironolactone and Ozanimod.	Multiple sclerosis [8A40]	[21]
Romidepsin	DMT5GNL	Moderate	Decreased clearance of Spironolactone due to the transporter inhibition by Romidepsin.	Mycosis fungoides [2B01]	[43]
Prochlorperazine	DM53SRA	Moderate	Additive hypotensive effects by the combination of Spironolactone and Prochlorperazine.	Nausea/vomiting [MD90]	[22]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Spironolactone and Promethazine.	Nausea/vomiting [MD90]	[22]
Sibutramine	DMFJTDI	Moderate	Increased risk of hyponatremia by the combination of Spironolactone and Sibutramine.	Obesity [5B80-5B81]	[27]
S-297995	DM26IH8	Moderate	Decreased metabolism of Spironolactone caused by S-297995 mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[20]
Rofecoxib	DM3P5DA	Moderate	Antagonize the effect of Spironolactone when combined with Rofecoxib.	Osteoarthritis [FA00-FA05]	[26]
Valdecoxib	DMAY7H4	Moderate	Antagonize the effect of Spironolactone when combined with Valdecoxib.	Osteoarthritis [FA00-FA05]	[26]
Diclofenac	DMPIHLS	Moderate	Antagonize the effect of Spironolactone when combined with Diclofenac.	Osteoarthritis [FA00-FA05]	[26]
Naproxen	DMZ5RGV	Moderate	Antagonize the effect of Spironolactone when combined with Naproxen.	Osteoarthritis [FA00-FA05]	[26]
MK-4827	DMLYGH4	Moderate	Decreased clearance of Spironolactone due to the transporter inhibition by MK-4827.	Ovarian cancer [2C73]	[44]
Etodolac	DM6WJO9	Moderate	Antagonize the effect of Spironolactone when combined with Etodolac.	Pain [MG30-MG3Z]	[26]
Diflunisal	DM7EN8I	Moderate	Antagonize the effect of Spironolactone when combined with Diflunisal.	Pain [MG30-MG3Z]	[26]
Ibuprofen	DM8VCBE	Moderate	Antagonize the effect of Spironolactone when combined with Ibuprofen.	Pain [MG30-MG3Z]	[26]
Nabumetone	DMAT2XH	Moderate	Antagonize the effect of Spironolactone when combined with Nabumetone.	Pain [MG30-MG3Z]	[26]
Piroxicam	DMTK234	Moderate	Antagonize the effect of Spironolactone when combined with Piroxicam.	Pain [MG30-MG3Z]	[26]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Spironolactone and Safinamide.	Parkinsonism [8A00]	[21]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Spironolactone and Rasagiline.	Parkinsonism [8A00]	[21]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Spironolactone caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[45]
Ketorolac	DMI4EL5	Moderate	Antagonize the effect of Spironolactone when combined with Ketorolac.	Postoperative inflammation [1A00-CA43]	[26]
Bromfenac	DMKB79O	Moderate	Antagonize the effect of Spironolactone when combined with Bromfenac.	Postoperative inflammation [1A00-CA43]	[26]
Relugolix	DMK7IWL	Major	Decreased clearance of Spironolactone due to the transporter inhibition by Relugolix.	Prostate cancer [2C82]	[46]
Silodosin	DMJSBT6	Moderate	Decreased clearance of Spironolactone due to the transporter inhibition by Silodosin.	Prostate hyperplasia [GA90]	[47]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Spironolactone and Levomepromazine.	Psychotic disorder [6A20-6A25]	[22]
Fluphenazine	DMIT8LX	Moderate	Additive hypotensive effects by the combination of Spironolactone and Fluphenazine.	Psychotic disorder [6A20-6A25]	[22]
Triflupromazine	DMKFQJP	Moderate	Additive hypotensive effects by the combination of Spironolactone and Triflupromazine.	Psychotic disorder [6A20-6A25]	[22]
Riociguat	DMXBLMP	Moderate	Decreased metabolism of Spironolactone caused by Riociguat mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[33]
Meloxicam	DM2AR7L	Moderate	Antagonize the effect of Spironolactone when combined with Meloxicam.	Rheumatoid arthritis [FA20]	[26]
Sulindac	DM2QHZU	Moderate	Antagonize the effect of Spironolactone when combined with Sulindac.	Rheumatoid arthritis [FA20]	[26]
Celecoxib	DM6LOQU	Moderate	Antagonize the effect of Spironolactone when combined with Celecoxib.	Rheumatoid arthritis [FA20]	[26]
Oxaprozin	DM9UB0P	Moderate	Antagonize the effect of Spironolactone when combined with Oxaprozin.	Rheumatoid arthritis [FA20]	[26]
Flurbiprofen	DMGN4BY	Moderate	Antagonize the effect of Spironolactone when combined with Flurbiprofen.	Rheumatoid arthritis [FA20]	[26]
Fenoprofen	DML5VQ0	Moderate	Antagonize the effect of Spironolactone when combined with Fenoprofen.	Rheumatoid arthritis [FA20]	[26]
Tolmetin	DMWUIJE	Moderate	Antagonize the effect of Spironolactone when combined with Tolmetin.	Rheumatoid arthritis [FA20]	[26]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Spironolactone and Quetiapine.	Schizophrenia [6A20]	[22]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Spironolactone and Mesoridazine.	Schizophrenia [6A20]	[22]
Thioridazine	DM35M8J	Moderate	Additive hypotensive effects by the combination of Spironolactone and Thioridazine.	Schizophrenia [6A20]	[22]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Spironolactone and Aripiprazole.	Schizophrenia [6A20]	[22]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Spironolactone and Iloperidone.	Schizophrenia [6A20]	[22]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Spironolactone and Paliperidone.	Schizophrenia [6A20]	[22]
Haloperidol	DM96SE0	Moderate	Additive hypotensive effects by the combination of Spironolactone and Haloperidol.	Schizophrenia [6A20]	[22]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Spironolactone and Perphenazine.	Schizophrenia [6A20]	[22]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Spironolactone and Molindone.	Schizophrenia [6A20]	[22]
Chlorpromazine	DMBGZI3	Moderate	Additive hypotensive effects by the combination of Spironolactone and Chlorpromazine.	Schizophrenia [6A20]	[22]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Spironolactone and Thiothixene.	Schizophrenia [6A20]	[22]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Spironolactone and Trifluoperazine.	Schizophrenia [6A20]	[22]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Spironolactone and Risperidone.	Schizophrenia [6A20]	[22]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Spironolactone and Amisulpride.	Schizophrenia [6A20]	[22]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Spironolactone and Asenapine.	Schizophrenia [6A20]	[22]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Spironolactone caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[33]
Docetaxel	DMDI269	Moderate	Decreased clearance of Spironolactone due to the transporter inhibition by Docetaxel.	Solid tumour/cancer [2A00-2F9Z]	[48]
Taxol	DMUOT9V	Moderate	Decreased clearance of Spironolactone due to the transporter inhibition by Taxol.	Solid tumour/cancer [2A00-2F9Z]	[48]
Pomalidomide	DMTGBAX	Moderate	Decreased metabolism of Spironolactone caused by Pomalidomide mediated inhibition of CYP450 enzyme.	Systemic sclerosis [4A42]	[33]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Spironolactone due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[49]
Apixaban	DM89JLN	Moderate	Decreased metabolism of Spironolactone caused by Apixaban mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[20]
Tacrolimus	DMZ7XNQ	Major	Increased risk of hyperkalemia by the combination of Spironolactone and Tacrolimus.	Transplant rejection [NE84]	[50]
Trimethoprim	DMM7CHK	Major	Increased risk of hyperkalemia by the combination of Spironolactone and Trimethoprim.	Urinary tract infection [GC08]	[51]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Spironolactone and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[22]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Spironolactone and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[52]
-----------


⏷ Show the Full List of 130 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Docusate sodium	E00563	23673837	Surfactant
Quinoline yellow WS	E00309	24671	Colorant
Sodium benzoate	E00432	517055	Antimicrobial preservative; lubricant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Calcium sulfate anhydrous	E00303	24497	Desiccant; Diluent
Calcium sulfate dihydrate	E00315	24928	Desiccant; Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 29 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Spironolactone 100 mg tablet	100 mg	Oral Tablet	Oral
Spironolactone 25 mg tablet	25 mg	Oral Tablet	Oral
Spironolactone 50 mg tablet	50 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Spironolactone FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2875).
3	Spironolactone in Covid-19 Induced ARDS
4	BDDCS applied to over 900 drugs
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7	Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals. Toxicology. 2004 Feb 15;195(2-3):177-86. doi: 10.1016/j.tox.2003.09.012.
8	Amiloride, spironolactone, and potassium chloride in thiazide-treated hypertensive patients. Clin Pharmacol Ther. 1980 Apr;27(4):533-43. doi: 10.1038/clpt.1980.75.
9	Pregnane X receptor mediates the induction of P-glycoprotein by spironolactone in HepG2 cells. Toxicology. 2011 Jul 11;285(1-2):18-24. doi: 10.1016/j.tox.2011.03.015. Epub 2011 Apr 1.
10	Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
11	Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease. Toxicol Sci. 2012 Oct;129(2):346-62. doi: 10.1093/toxsci/kfs208. Epub 2012 Jun 14.
12	Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001 Apr;37(5):1228-33. doi: 10.1016/s0735-1097(01)01116-0.
13	Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
14	Receptor-dependent regulation of the CYP3A4 gene. Toxicology. 2002 Dec 27;181-182:199-202.
15	Spironolactone induces apoptosis in human mononuclear cells. Association between apoptosis and cytokine suppression. Apoptosis. 2006 Apr;11(4):573-9. doi: 10.1007/s10495-006-4919-3.
16	Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006): 49-58. [PMID: 16373465]
17	Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
18	Product Information. Aldactone (spironolactone). Searle, Skokie, IL.
19	Multum Information Services, Inc. Expert Review Panel.
20	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
21	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
22	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
23	Adachi Y, Suzuki H, Sugiyama Y "Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in Situ and in Vivo." Pharm Res 20 (2003): 1163-9. [PMID: 12948013]
24	Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
25	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
26	Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
27	Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
28	Product Information. Dificid (fidaxomicin). Optimer Pharmaceuticals, San Diego, CA.
29	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
30	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
31	Yassa R, Nastase C, Camille Y, Henderson M, Belzile L, Beland F "Carbamazepine, diuretics, and hyponatremia: a possible interaction." J Clin Psychiatry 48 (1987): 281-3. [PMID: 3597330]
32	Product Information. Aptiom (eslicarbazepine). Sunovion Pharmaceuticals Inc, Marlborough, MA.
33	Cerner Multum, Inc. "Australian Product Information.".
34	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
35	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
36	Product Information. Midamor (amiloride). Merck & Co, Inc, West Point, PA.
37	Product Information. Tekturna (aliskiren). Novartis Pharmaceuticals, East Hanover, NJ.
38	Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812. [PMID: 14525902]
39	McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970): 58-70. [PMID: 5410663]
40	Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
41	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
42	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
43	Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
44	Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
45	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
46	Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
47	Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
48	Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
49	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
50	Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14. [PMID: 10996582]
51	Canaday DH, Johnson JR "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 438. [PMID: 8304666]
52	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.